IN2014CN02169A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02169A IN2014CN02169A IN2169CHN2014A IN2014CN02169A IN 2014CN02169 A IN2014CN02169 A IN 2014CN02169A IN 2169CHN2014 A IN2169CHN2014 A IN 2169CHN2014A IN 2014CN02169 A IN2014CN02169 A IN 2014CN02169A
- Authority
- IN
- India
- Prior art keywords
- present
- azulenes
- dysmenorrhea
- vasopressin
- oxa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The present invention provides 4H 6H 5 oxa 2 3 10b triaza benzo[e]azulenes which act as V1a receptor modulators and in particular as Via receptor antagonists their manufacture pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea male or female sexual dysfunction hypertension chronic heart failure inappropriate secretion of vasopressin liver cirrhosis nephrotic syndrome anxiety depressive disorders obsessive compulsive disorder autistic spectrum disorders schizophrenia and aggressive behavior.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11182796 | 2011-09-26 | ||
| PCT/EP2012/068721 WO2013045373A1 (en) | 2011-09-26 | 2012-09-24 | Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02169A true IN2014CN02169A (en) | 2015-05-29 |
Family
ID=46881068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2169CHN2014 IN2014CN02169A (en) | 2011-09-26 | 2012-09-24 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8828989B2 (en) |
| EP (1) | EP2760871B1 (en) |
| JP (1) | JP5909554B2 (en) |
| KR (1) | KR101682777B1 (en) |
| CN (1) | CN103827121B (en) |
| AR (1) | AR087999A1 (en) |
| AU (1) | AU2012314593B2 (en) |
| BR (1) | BR112014006945A2 (en) |
| CA (1) | CA2844581A1 (en) |
| CL (1) | CL2014000717A1 (en) |
| CO (1) | CO6870036A2 (en) |
| CR (1) | CR20140092A (en) |
| EA (1) | EA024990B1 (en) |
| EC (1) | ECSP14013271A (en) |
| IN (1) | IN2014CN02169A (en) |
| MA (1) | MA35535B1 (en) |
| MX (1) | MX2014003643A (en) |
| PE (1) | PE20141397A1 (en) |
| SG (1) | SG2014010607A (en) |
| TW (1) | TWI553013B (en) |
| UA (1) | UA111623C2 (en) |
| WO (1) | WO2013045373A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE249465T1 (en) | 1999-01-19 | 2003-09-15 | Ortho Mcneil Pharm Inc | TRICYCLIC BENZODIAZEPINES AS VASOPRESSIN ANTAGONISTS |
| US6765004B1 (en) | 1999-06-17 | 2004-07-20 | Ortho-Mcneil Pharmaceutical, Inc. | Indoloazepines as vasopressin receptor antagonists |
| GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| US7119088B2 (en) | 2003-02-19 | 2006-10-10 | Pfizer Inc. | Triazole compounds useful in therapy |
| GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| US7456170B2 (en) * | 2004-08-25 | 2008-11-25 | Pfizer Inc. | Triazolobenzodiazepines and their use as vasopressin antagonists |
| DK2358714T3 (en) | 2008-11-18 | 2012-08-20 | Hoffmann La Roche | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES |
| MX2011005596A (en) | 2008-11-28 | 2011-06-16 | Hoffmann La Roche | Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists. |
-
2012
- 2012-08-23 US US13/592,493 patent/US8828989B2/en active Active
- 2012-09-24 WO PCT/EP2012/068721 patent/WO2013045373A1/en active Application Filing
- 2012-09-24 CN CN201280046689.0A patent/CN103827121B/en active Active
- 2012-09-24 KR KR1020147010783A patent/KR101682777B1/en active IP Right Grant
- 2012-09-24 PE PE2014000394A patent/PE20141397A1/en not_active Application Discontinuation
- 2012-09-24 JP JP2014532331A patent/JP5909554B2/en active Active
- 2012-09-24 CA CA2844581A patent/CA2844581A1/en not_active Abandoned
- 2012-09-24 UA UAA201403611A patent/UA111623C2/en unknown
- 2012-09-24 AU AU2012314593A patent/AU2012314593B2/en not_active Ceased
- 2012-09-24 EA EA201490558A patent/EA024990B1/en not_active IP Right Cessation
- 2012-09-24 MX MX2014003643A patent/MX2014003643A/en unknown
- 2012-09-24 BR BR112014006945A patent/BR112014006945A2/en not_active IP Right Cessation
- 2012-09-24 IN IN2169CHN2014 patent/IN2014CN02169A/en unknown
- 2012-09-24 EP EP12761740.5A patent/EP2760871B1/en active Active
- 2012-09-24 SG SG2014010607A patent/SG2014010607A/en unknown
- 2012-09-25 TW TW101135168A patent/TWI553013B/en not_active IP Right Cessation
- 2012-09-25 AR ARP120103514A patent/AR087999A1/en unknown
-
2014
- 2014-01-31 CO CO14020668A patent/CO6870036A2/en not_active Application Discontinuation
- 2014-02-26 CR CR20140092A patent/CR20140092A/en unknown
- 2014-03-24 CL CL2014000717A patent/CL2014000717A1/en unknown
- 2014-03-26 EC ECSP14013271 patent/ECSP14013271A/en unknown
- 2014-04-15 MA MA36919A patent/MA35535B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2760871B1 (en) | 2018-07-18 |
| KR20140079790A (en) | 2014-06-27 |
| PE20141397A1 (en) | 2014-10-13 |
| TWI553013B (en) | 2016-10-11 |
| CA2844581A1 (en) | 2013-04-04 |
| MX2014003643A (en) | 2014-04-30 |
| US8828989B2 (en) | 2014-09-09 |
| NZ620653A (en) | 2016-03-31 |
| US20130079333A1 (en) | 2013-03-28 |
| EA024990B1 (en) | 2016-11-30 |
| ECSP14013271A (en) | 2014-05-31 |
| MA35535B1 (en) | 2014-10-02 |
| CN103827121B (en) | 2016-08-03 |
| WO2013045373A1 (en) | 2013-04-04 |
| EP2760871A1 (en) | 2014-08-06 |
| CR20140092A (en) | 2014-03-20 |
| KR101682777B1 (en) | 2016-12-05 |
| BR112014006945A2 (en) | 2017-04-04 |
| EA201490558A1 (en) | 2014-06-30 |
| AU2012314593B2 (en) | 2016-09-29 |
| SG2014010607A (en) | 2014-05-29 |
| CN103827121A (en) | 2014-05-28 |
| AU2012314593A8 (en) | 2014-03-27 |
| TW201315737A (en) | 2013-04-16 |
| JP5909554B2 (en) | 2016-04-26 |
| JP2014527993A (en) | 2014-10-23 |
| CL2014000717A1 (en) | 2014-10-03 |
| UA111623C2 (en) | 2016-05-25 |
| AU2012314593A1 (en) | 2014-02-20 |
| AR087999A1 (en) | 2014-04-30 |
| CO6870036A2 (en) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ603223A (en) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | |
| MY160457A (en) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin via receptor antagonists | |
| MX2014003600A (en) | Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists. | |
| MY160977A (en) | Heterobiaryl-cyclohexyl-tetraazabenzo[e] azulenes | |
| CO6341478A2 (en) | DIHYDRO-TETRAAZABENZOAZULEN ARILCICLOHEXILETERES FOR USE AS VASOPRESINE V1A RECEIVER ANTAGONISTS | |
| BR112012024306A2 (en) | aryl cyclohexyl tetraazabenzo [e] azulenes | |
| JOP20180103B1 (en) | PHARMACEUTICAL COMPOSITION of CARBETOCIN | |
| IN2014DN09804A (en) | ||
| IN2014CN02515A (en) | ||
| TW200734343A (en) | Indol-3-yl-carbonyl-spiro-piperidine derivatives | |
| BR112012025942A2 (en) | aryl / heteroaryl cyclohexenyl tetraazabenzo [e] azulenes as vasopressin antagonists | |
| PH12016500919A1 (en) | Spiro-oxazolones | |
| MX2016009501A (en) | Spiro-oxazolones. | |
| IN2014CN02169A (en) | ||
| PH12017500891A1 (en) | Spiro-thiazolones |